Walgreens: A Cleared Work Queue and an Unreversed Claim

In the Walgreens uncollected prescriptions case, Walgreens agreed to a $106.8 million settlement over allegations that it billed government health care programs for prescriptions never dispensed. The government’s account reached inside the pharmacy’s software: orders disappeared from local work queues while claims remained unreversed. If you handled those queues, central records or billing corrections, you may know where the prescription went after the store stopped seeing it.

The Justice Department announced the resolution on September 13, 2024. It covered three whistleblower cases through two agreements: one concerning Walgreens’ central prescription status and another concerning undelivered Medicare Part B medicines, equipment and supplies.

The central-status agreement covered allegations involving Medicare, Medicaid, TRICARE, the Federal Employees Health Benefits Program and the Department of Veterans Affairs. Its alleged conduct ran from June 25, 2013, through May 5, 2020.

How Intercom Plus Moved Orders Out of View

The government alleged that Walgreens configured Intercom Plus to move unsold or undeleted prescription orders off local servers after 29 days. The reason given in the uncollected-prescription agreement was server storage capacity. The orders acquired an Unaccounted-For Status and moved to the central server.

Intercom Plus connected Walgreens stores and coordinated claims processing with payers and their payment agents. Moving an order within that system could therefore affect what staff saw without settling the financial transaction behind it. The government’s allegation identifies the precise break:

The agreement then alleges that Walgreens had no separate back-end process to review and resolve those central-server orders. As a result, the claims were neither deleted in Intercom Plus nor reversed. The government alleged that Walgreens knowingly billed for prescriptions customers never picked up or received.

We find the priorities in that alleged design absurd. Storage capacity had a solution. The unresolved claims allegedly had none. Removing the work from the pharmacist’s screen left the government paying for medicine the patient never received, according to the government’s account.

That is what makes this case useful to someone inside a pharmacy business. The local queue, the central status and the payer’s claim history can tell different parts of the same story. An employee who understands the handoff can explain why an order stopped appearing as unfinished work and what was supposed to happen next.

The Claim, the Medicine and the Money

The Walgreens allegations connect an order that disappeared from the store’s screen to a government claim that stayed paid. The pharmacy’s dispensing records, central status and payment history let us follow that same prescription across the break.

New York Medicaid’s pharmacy transaction guide shows how a prescription reference connects billing, reversal and rebill transactions. For the alleged Walgreens failure, that kind of transaction trail matters more than whether an order still appears in a local queue. A reversal acknowledgment and the payer’s refund records show what happened after an attempted correction.

The same prescription also carries the information used to obtain approval. In false prior-authorization cases, who supplied the prescriber’s answers can be the issue. Here, the government’s allegation concerned whether Walgreens supplied the medicine after processing the order.

Medicare Part D Adds a Reporting Record

A pharmacy’s correction also has to reach the plan’s federal reporting. In its July 3, 2013 adjustment guidance, CMS says a drug never dispensed calls for recouping the cost and deleting the Prescription Drug Event. A wrong product code on a claim instead calls for correcting the product and financial fields. For an uncollected prescription, we follow whether the payment correction reached the plan’s reporting as well as the pharmacy’s system.

The Separate Medicare Part B Allegations

The Part B agreement resolved allegations that Walgreens billed for prescription medications, durable medical equipment and related supplies that beneficiaries never received. The alleged billing ran from January 1, 2009, through December 31, 2015.

A former Walgreens district pharmacy supervisor brought that whistleblower case. Under the separate Part B settlement, Walgreens agreed to pay $9 million to the United States.

The common question is whether the billed item reached the beneficiary. The central-status agreement gives a detailed account of software and unresolved orders. The Part B agreement describes the medicines, equipment and supplies allegedly never dispensed or delivered. Keeping those accounts separate lets an insider recognize the transaction they actually handled.

The Prior Refunds Inside the Headline

The central-status agreement set a total settlement amount of approximately $97.8 million, including a credit for approximately $66.3 million Walgreens had already refunded. It required $31.5 million in new money payable to the United States and participating Medicaid states. The earlier refunds exceeded the new money required under that agreement.

That comparison changes how the announcement reads. A substantial part of the resolution recognized money already returned. We think the headline means more when the reader can see the refunds inside it and the additional payment Walgreens agreed to make.

The agreement also records what Walgreens did about the system. Its compliance department disclosed to the Department of Health and Human Services Office of Inspector General a substantial overpayment involving unaccounted-for orders. Walgreens preserved and disclosed documents and claims data, retained an independent consulting firm to help quantify improper billing, and implemented a chain-wide Intercom Plus enhancement.

The company’s disclosure described unaccounted-for orders still undispensed or undelivered after 30 days. The agreement records refunds to federal healthcare programs or their payment agents, and Justice Department credit for disclosure, cooperation and remediation. For someone who worked on the response, the history includes the internal description of the problem, the claims used to quantify it and the payments made to return the money.

The Department of Health and Human Services Office of Inspector General and the National Association of Medicaid Fraud Control Units assisted in the investigations.

DaVita Rx Shows the Delivery Side of the Same Question

In its December 14, 2017 DaVita Rx settlement announcement, the Justice Department described allegations involving unshipped drugs, returned shipments and dispensing without required proof of delivery, refill requests or consent.

A package that never left the pharmacy and a package that came back have different histories. The government’s allegations against DaVita Rx covered both, along with missing support for dispensing. An employee familiar with shipping or returns can explain which history belongs to a particular claim and where a payment correction should appear.

The comparison helps locate the failure. Walgreens’ central-status allegations focused on orders leaving the local queue and claims remaining unresolved. The DaVita Rx allegations show why shipment, receipt and return records also matter.

What an Insider Can Explain

An insider can connect the system’s status to what employees actually saw and did. In the central-status cases, a former Walgreens pharmacy manager was among the whistleblowers. The district supervisor’s separate Part B case brought another operational view to the same resolution.

For a store employee, the useful knowledge may concern an order that stopped appearing in the work queue. For a systems employee, it may concern what the central status meant and whether any process reviewed it. A billing or reconciliation employee may understand the reversal response, payer refund or later reporting correction. We work with that firsthand account to connect the prescription, payment and company’s decisions.

The central-status agreement provided approximately $14.9 million for the two whistleblowers. The Part B agreement provided a $1.62 million whistleblower share.

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

You Know What Happened After the Order Disappeared

If your work revealed uncollected orders and government payments left standing, tell our whistleblower experts where the process broke down. We build the case with you around the system behavior, the claims and the decisions behind them, and bring in pharmacy fraud whistleblower lawyers who understand dispensing and reimbursement. You bring the view from inside the business, and we stay beside you all the way.